Menopause brings a host of changes. One of the most frustrating for many women is the unexplained weight gain around the belly. However, there is currently a great deal of progress being made in medical research in this area. Leading experts in the field of menopause medicine view the combination of GLP-1 medications and menopausal hormone therapy as one of the most promising strategies for regaining metabolic health, muscle strength, and self-confidence in midlife over the long term.

“Menopausal Metabolic Syndrome”: What’s Happening in the Body?

To understand how we can counteract this, it’s worth taking a closer look at the biological processes involved. Perimenopause is not a gentle, gradual decline in hormone levels, but rather an often chaotic phase that can last 7 to 10 years. As estrogen levels fluctuate and eventually decline, the distribution of fat in the body changes drastically.

In current research, the term “metabolic syndrome of menopause” has become established. It describes a vicious cycle into which many women unwittingly fall:

• •Shift in fat distribution: Instead of storing fat under the skin (subcutaneously), the body now increasingly stores it as so-called visceral fat deep within the abdominal cavity, where it surrounds the internal organs. In a premenopausal woman, this fat accounts for about 8–10% of body fat—after menopause, this figure can double or even triple to 20–25%!
• •The inflammation spiral: This visceral fat is not passive. It produces pro-inflammatory cytokines that travel throughout the body and put strain on the joints, intestines, and brain.
• •Insulin Resistance: Due to inflammation and estrogen deficiency, cells become less sensitive to insulin. The body needs more and more insulin to transport blood sugar into the cells. High insulin levels, in turn, promote the storage of even more belly fat.
• •Sleep & Cortisol: The drop in estrogen and progesterone often leads to severe sleep disturbances. Lack of sleep increases stress and causes us to reach for simple carbohydrates—which further fuels the cycle.

The bottom line: The battle against belly fat in midlife can hardly be won by willpower alone. It is a biological process that collides with a modern, often sedentary lifestyle characterized by highly processed foods.

GLP-1 Medications: From the Myth of a Miracle Cure to Targeted Therapy

GLP-1 stands for glucagon-like peptide-1. These medications (such as semaglutide/Ozempic or tirzepatide/Mounjaro) mimic a natural hormone produced in our intestines. An interesting fun fact from medical history: The first drug of this kind was approved in 2005 and inspired by a fascinating discovery—the peptide exendin-4 from the saliva of the Gila monster (a lizard native to the American Southwest), which is very similar to GLP-1 but remains active in the body much longer!

How do they work? They signal satiety to the brain, slow gastric emptying, and massively improve insulin sensitivity. But what makes them special isn’t just appetite suppression: Through the targeted reduction of visceral fat, inflammation levels in the body drop significantly, and blood sugar and blood pressure improve measurably.

Initially, many gynecologists in the medical community viewed these medications with skepticism—images of extreme, rapid weight loss on social media raised concerns that users were losing a dangerous amount of muscle mass. However, after an intensive review of the data from the past 20 years and discussions with obesity experts, the picture has changed. Today, GLP-1 medications are used in specialized clinics—though under strict medical supervision.

The Power Duo: Why GLP-1 and MHT Work Better Together

An exciting study from 2024 (published in the journal Menopause) yielded groundbreaking results: Women who took a GLP-1 medication while also undergoing menopausal hormone therapy (MHT) lost significantly more weight at every checkpoint (after 3, 6, 9, and 12 months) and improved their metabolic markers more than women who received only the medication. They reached clinically significant milestones (such as losing 5% or 10% of their starting weight) much more frequently.

The reasons for this are clear: MHT naturally inhibits the accumulation of abdominal fat by up to 60%. It also protects blood vessel flexibility, improves sleep, lifts mood, and protects bones. All of this gives women the energy and resilience they need to stay active in their daily lives. When combined with the blood sugar-regulating effect of GLP-1, a synergistic effect is created.

The absolute must: Protect your muscle mass!

GLP-1 often suppresses appetite so strongly that many women unconsciously eat far too little—especially too little protein. The body then draws on the muscles as an energy source. This is one of the key warnings that specialized menopause doctors repeatedly emphasize. The natural aging process and menopause are already taking a toll on our muscles (sarcopenia).

Our muscles are, alongside the ovaries, the most important so-called geroprotective (age-protective) organ. They determine our basal metabolic rate (BMR)—that is, how many calories we burn at rest—and soak up glucose like a sponge.

In modern menopause clinics, the prescription of GLP-1 is therefore subject to strict conditions:

• •Bone density scan beforehand: A baseline measurement is essential, as muscle and bone development are closely linked (ironically, the greatest bone loss occurs precisely during perimenopause).
• •DEXA scans or body composition scales: Progress is tracked not on a regular scale, but through precise body composition analysis.

The 10-Percent Rule: If a patient loses more than 10% of her muscle mass during therapy, the dose must be adjusted or the medication paused.

Prevention & Action: Your Roadmap for Practice

If you feel stuck, information is your most important weapon. A simple standard blood test is often no longer sufficient in midlife.

The 5 Most Important Lab Values You Should Know Now

Current recommendations in menopause medicine suggest that women aged 35 and older experiencing hormonal imbalances should specifically ask their doctor for the following values—even before considering medication:

• •Fasting insulin & fasting blood sugar: These two values can be used to calculate the so-called HOMA-IR index (free calculators are available online). It should be below 2. A higher value serves as an early warning sign for insulin resistance, long before blood sugar levels spiral out of control.
• •Ferritin (iron stores): The storage level is crucial, not just the iron in the blood. A value below 60 can already trigger symptoms such as exhaustion, hair loss, and brain fog—often mistaken for menopause symptoms!
• •Vitamin D: The value should ideally be between 60 and 100. It protects the bones, supports muscle strength, and has anti-inflammatory effects.
• •Lipoprotein(a): A specific, very small cholesterol particle strongly associated with cardiovascular disease. In women, this level often rises during menopause and should be checked.

High-Sensitivity C-Reactive Protein (hs-CRP): A general marker for silent inflammation in the body, which is often elevated in cases of metabolic dysfunction.

Your checklist for GLP-1 therapy (or as a general prevention guide):

• •Prioritize protein: Aim for 1.5 to 1.8 grams of protein per kilogram of your ideal body weight per day (that’s usually 80 to 120 grams daily).
• •Strength training is a must: Work out 2 to 3 times a week. Muscles are your metabolic shield.
• •Hydration: GLP-1 reduces the sensation of thirst. Drink plenty of water and avoid carbonated beverages (these promote bloating, as the medication slows digestion).
• •Increase fiber intake gradually: To avoid constipation and give your sluggish stomach time to adjust.

Healthy weight loss pace: Limit weight loss to 0.5 to a maximum of 1 kg per week. Faster weight loss significantly increases the risk of muscle loss and gallstones.

Conclusion: Strong, not skinny

This isn’t about fitting into an old pair of jeans at any cost. It’s about longevity—a long, healthy, and vibrant life. The combination of MHT and GLP-1 offers modern women’s medicine an unprecedented opportunity to effectively treat the insidious metabolic syndrome of menopause. You’re not broken, and it’s not your fault. Educate yourself, request the right lab tests, and reclaim your well-being!

Sources

1. Haver MC. unPAUSED: The Perimenopause Masterclass: Anxiety, Brain Fog, Broken Sleep, Weight Gain & GLP-1s. Podcast-Folge (2026).
2. Deane AM et al. The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill. Crit Care 14, 239 (2010). https://doi.org/10.1186/cc9281. PMID: 20979668.
3. U.S. Department of Veterans Affairs. Diabetes drug from Gila monster venom. Research in Action (2019). https://www.research.va.gov/research_in_action/Diabetes-drug-from-Gila-monster-venom.cfm
4. Hurtado, M. D. et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024 Apr 1;31(4):266-274. doi: 10.1097/GME.0000000000002310. Epub 2024 Mar 5. PMID: 38446869.
5. The Lancet Public Health. Time to tackle obesogenic environments. Lancet Public Health. 2025 Mar;10(3):e165. doi: 10.1016/S2468-2667(25)00049-0. PMID: 40044241.
6. Banas J et al. United States Long-Term Trends in Adult BMI (1959–2018): Unraveling the Roots of the Obesity Epidemic. Int J Environ Res Public Health 21, 73 (2024). doi: 10.3390/ijerph21010073. PMID: 38248537.
7. Centers for Disease Control and Prevention (CDC). Prevalence of Obesity and Severe Obesity Among Adults: United States. NCHS Data Brief 508 (2024). https://www.cdc.gov/nchs/products/databriefs/db508.htm
8. Montani JP et al. Dieting and weight cycling as risk factors for cardiometabolic diseases: who is really at risk?. Obes Rev 16, 7-18 (2015). doi: 10.1111/obr.12251. PMID: 25614199.
9. Lutz M et al. Ultraprocessed Foods and Neuropsychiatric Outcomes: Putative Mechanisms. Nutrients. 2025 Mar 30;17(7):1215. doi: 10.3390/nu17071215. PMID: 40218973.